Home|Journals|Articles by Year|Audio Abstracts
 

Case Report



Autoimmune polyglandular syndrome type III which accompanies to multiple sclerosis: A case report

Ahmet Gorgel, Mehmet Tecellioglu, Cem Cankaya.




Abstract
Cited by 1 Articles

Autoimmune polyglandular syndrome type III (APS III) is characterised by autoimmune destruction of various endocrine and non-endocrine tissues. It differs from APS I and APS II in terms of without adrenal involvement. Although APS III includes a series of autoimmune disorders, it is rarely associated with multiple sclerosis (MS). A 41-year-old female patient had diplopia, visual blurring, dizziness, and giddiness for 2 weeks. In her medical history, she had a diagnosis of MS and using Teriflunomide. It was detected positivity of antinuclear antibody (ANA), anti-thyroid peroxidase (Anti-TPO) and anti-thyroglobulin (Anti-TG) antibodies. Based on these results, the patient with MS who has chronic autoimmune thyroiditis and primary ovarian failure was diagnosed with APS III. The coexistence of APS-III and MS is a rare clinical entity. Moreover, hypothyroidism has been detected during teriflunomide therapy in the patient. Hypothyroidism was most likely a component of APS-III in our case, but it may also have been triggered by teriflunomide.

Key words: Autoimmune polyglandular syndrome (APS) type III; multiple sclerosis; teriflunomide






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.